UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13D

(Rule 13d-101)

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO

§ 240.13d-2(a)

(Amendment No. 3)¹

Quorum Health Corporation

(Name of Issuer)

Common Stock, par value $0.0001

(Title of Class of Securities)

74909E106

(CUSIP Number)

STEVE WOLOSKY, ESQ.

OLSHAN FROME WOLOSKY LLP

1325 Avenue of the Americas

New York, New York 10019

(212) 451-2300

(Name, Address and Telephone Number of Person

Authorized to Receive Notices and Communications)

May 5, 2020

(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box ¨.

Note:  Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits.  See § 240.13d-7 for other parties to whom copies are to be sent.

1              The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

The following constitutes Amendment No. 3 to the Schedule 13D filed by the undersigned (“Amendment No. 3”). This Amendment No. 3 amends the Schedule 13D as specifically set forth herein.

Item 4 is hereby amended to add the following:

On May 5, 2020, the Reporting Persons’ legal counsel delivered a letter (the “Letter”) to the Issuer’s board of directors (the “Board”) on behalf of the Reporting Persons, to supplement the Reporting Persons’ April 29, 2020 letter requesting that the Board exercise its “fiduciary out” and terminate the Restructuring Support Agreement (the “RSA”). In the Letter, the Reporting Persons submitted a plan term sheet (the “Term Sheet”) for a Superior Alternative Transaction, as such term is described in Section 8(c) of the RSA.

The Letter stated the Reporting Persons’ belief that the Term Sheet outlines a plan of reorganization far better for all of the Issuer’s stakeholders than the Issuer’s current Plan of Reorganization (the “Plan”), and that it properly recognizes the stakeholders’ respective legal rights. The Reporting Persons further stated their belief that the Superior Alternative Transaction summarized in the Term Sheet adheres to the same general structure as the Plan and improves upon its terms by (i) guaranteeing a cash recovery for the First Lien Lenders in an amount up to $100 million greater than that provided for in the Plan, (ii) providing the Senior Notes with take back paper equivalent to 100% of the present value of the Senior Notes Claims as compared to the Issuer’s position of 9.5%, (iii) reinstating all equity interest holders and (iv) providing for a backstopped equity rights offering correctly raised at equity, the fulcrum security. The Letter noted that this rights offering would be sized in the amount and to the extent necessary to fund the First Lien Loan Claim Paydown Amount, pay all Admin Fees at emergence and provide sufficient operating cash to the post-emergence balance sheet, and that Mudrick would backstop at least $50 million of this equity rights offering after it has had an opportunity to review matters further with the Issuer.

The Reporting Persons concluded the Letter by requesting a meeting with the Board and members of management at the earliest possible time and stated that, assuming that the Board agreed to proceed with the Superior Alternative Transaction at such time, it would be appropriate for Mudrick to designate a director to fill the current vacancy on the Board.

The foregoing description of the Letter does not purport to be complete and is qualified in its entirety by reference to the full text of the Letter, which is filed as Exhibit 99.1, and is incorporated herein by reference.

Item 7 is hereby amended to add the following exhibit:

SIGNATURES

After reasonable inquiry and to the best of his knowledge and belief, the undersigned certifies that the information set forth in this statement is true, complete and correct.

Dated: May 5, 2020